How do you value a SPAC? With a surge in SPAC IPOs resulting from the COVID-impacted economy, SPAC valuations should not be given equal consideration.
The private equity and credit markets held up remarkably well in the face of a global pandemic and are adjusting to the “new normal.” Market participants should go into 2021 with heightened vigilance as the impacts of the pandemic may not have yet entirely played out.
On track for recovery: Pandemic implications, not all doom or gloom.
In the November issue, Bloomberg publishes Mutarelli’s third-quarter analysis results of valuations and impairment testing, including potential goodwill impairment.
How are privately held unicorns’ valuations faring in the age of COVID?
In Q3 2020, secondary equity and credit markets rebounded, primary equity and levered finance markets reopened, and the price of risk declined.
Featured in the October issue, Mutarelli analyzes how to approach valuations and impairment testing when managing through the impacts of COVID.
As we head into Q4 2020, the new normal in private capital markets has fully set in, generally defined by prudence and caution, albeit a work in progress.
Business Development Company market participants are focused keenly on valuation in the wake of the novel coronavirus and the impact on their underlying portfolio investments.
Private asset valuations snapped back in Q2 as the economy began to reopen, and private capital investors took concrete steps to shore up portfolio companies.